Injection Pen Market. The global injection pen market is on track for substantial growth, with a forecasted compound annual ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

The therapy’s main competitor in the space is Sanofi and Regeneron’s Dupixent (dupilumab). It has been approved to treat CRSwCP along with multiple immune-mediated disorders including asthma and COPD.

Get detailed information on Dupilumab, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with eosinophilic esophagitis, expanding its market potential ...

The EMA’s decision marks an expansion from the initial EU approval for EoE treatment in adolescents and adults. Credit: Orawan Pattarawimonchai/Shutterstock. The ...

such as Dupixent for the treatment of chronic pruritus of unknown origin, bullous pemphigoid, and other potential indications; the ability of Regeneron’s collaborators, licensees, suppliers, or other ...

French pharma major Sanofi’s (Euronext: SAN) Dupixent (dupilumab), which notched up sales of 3.5 billion euros ($3.8 billion) in third-quarter 2024, +23.8% year-on-year, has picked up yet another ...

This is how biologic treatments can help. Dupixent (dupilumab) was the first biologic treatment approved for atopic dermatitis. It became available in 2017. It is currently approved for adults and ...